Angela Berry
Boehringer Ingelheim (United Kingdom)(GB)Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Cannabis and Cannabinoid Research, Pharmacological Receptor Mechanisms and Effects, Neurotransmitter Receptor Influence on Behavior, Estrogen and related hormone effects, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease(2019)144 cited
- → Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies(2006)67 cited
- → Identification of Highly Efficacious Glucocorticoid Receptor Agonists with a Potential for Reduced Clinical Bone Side Effects(2014)31 cited
- → Discovery and Optimization of p38 Inhibitors via Computer-Assisted Drug Design(2007)24 cited
- → 1,4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability(2011)21 cited
- → Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches(2014)21 cited
- → Morpholine containing CB2 selective agonists(2009)19 cited
- → Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores(2011)19 cited
- → Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model(2014)14 cited
- → Selective CB2 receptor agonists. Part 2: Structure–activity relationship studies and optimization of proline-based compounds(2014)14 cited